We evaluated correlates of adherence to PrEP, including daily oral tenofovir disoproxil
fumarate in combination emtricitabine (oral FTC/TDF) and the monthly dapivirine ring (ring) …

Background Half of new HIV acquisitions in Africa occur in adolescent girls and young
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …

Background: Several clinical trials have demonstrated the safety and effectiveness of oral
tenofovir disoproxil fumarate (TDF), with or without emtricitabine (FTC), as pre-exposure …

Introduction HIV incidence remains high among African adolescent girls and young women
(AGYW), who would benefit from pre‐exposure prophylaxis (PrEP). Strategies to increase …

Introduction Oral tenofovir disoproxil fumarate/emtricitabine pre‐exposure prophylaxis
(PrEP), introduced into South Africa (SA) in 2016, has increasingly become part of HIV …

Background Pre-exposure prophylaxis (PrEP) is highly effective and an important prevention
tool for African adolescent girls and young women (AGYW), but adherence and persistence …

Introduction Effective use of pre‐exposure prophylaxis (PrEP) has been low among
adolescent girls and young women (AGYW) in sub‐Saharan Africa. The MTN‐034/REACH …

Background HIV incidence among adolescents in southern Africa remains unacceptably
high. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention intervention but there …

Background Adolescent girls and young women in southern and eastern Africa have
adherence challenges with daily oral HIV pre-exposure prophylaxis (PrEP). High adherence …

Introduction Oral pre‐exposure prophylaxis (PrEP) has been scaled up; however, data from
real‐world settings are limited. We studied oral PrEP preference, uptake, adherence and …